Every 8-K that Bausch Health Companies Inc (BHC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow BHC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BHC filings page.
Bausch Health reported strong results for the quarter ended June 30, 2026. Total consolidated revenue was $2.85 billion, up 13% on a reported basis and 11% on an organic basis versus the prior-year quarter. Revenue excluding Bausch + Lomb grew 16% reported and 13% organic, led by the Salix segment, where sales rose 21%, and Solta Medical, up 38% reported.
GAAP net income attributable to Bausch Health was $258 million, up from $148 million, with GAAP diluted EPS of $0.68. Adjusted net income attributable to Bausch Health was $476 million, and adjusted diluted EPS was $1.26, up from $0.90. Adjusted EBITDA attributable to Bausch Health increased to $1.08 billion from $842 million. Cash provided by operating activities reached $671 million, compared with $289 million a year earlier.
As of June 30, 2026, cash and cash equivalents were $1.83 billion including restricted cash, against total long-term debt of $20.74 billion. Management raised 2026 guidance, targeting consolidated revenue of $10.79–$11.04 billion and adjusted EBITDA of $4.05–$4.18 billion, with higher outlooks for revenue, adjusted EBITDA and adjusted cash flows from operations for the business excluding Bausch + Lomb.
Bausch Health Companies Inc. announced that director Michael Goettler has resigned from its Board of Directors, effective June 30, 2026. He is leaving in connection with his appointment as President and Chief Executive Officer of Knoa Pharma LLC.
The company states that Mr. Goettler’s resignation was not due to any disagreement regarding its operations, policies or practices. A press release dated July 1, 2026, describing the resignation is furnished as Exhibit 99.1. Bausch Health describes itself as a global diversified pharmaceutical company with products across multiple therapeutic areas and a controlling interest in Bausch + Lomb Corporation.
Bausch Health Companies Inc. reported results of its Annual Meeting of Shareholders held on May 19, 2026. Shareholders elected all nominated directors, including new director Eiry W. Roberts, M.D., to serve until the 2027 annual meeting or earlier resignation or removal.
Shareholders also approved, on a non-binding advisory basis, the compensation of the Named Executive Officers as described in the company’s proxy materials. In addition, they appointed PricewaterhouseCoopers LLP as the independent registered public accounting firm through the 2027 annual meeting and authorized the board to set the auditors’ remuneration.
Bausch Health Companies Inc. reported strong Q1 2026 revenue growth but a large accounting loss driven by a goodwill charge. Consolidated revenue was $2.52 billion, up 12% year over year and 7% on an organic basis, led by 18% organic growth at Salix and 6% organic growth at Bausch + Lomb.
GAAP net loss attributable to Bausch Health was $1.423 billion, mainly from a $1.426 billion goodwill impairment tied to the Salix RED‑C program. On a non‑GAAP basis, adjusted net income attributable to Bausch Health rose to $296 million, with adjusted EPS of $0.78 versus $0.59 a year earlier and adjusted EBITDA attributable to Bausch Health of $837 million, up from $661 million.
The company generated $230 million of operating cash in the quarter and ended March 31, 2026 with $1.299 billion in cash and cash equivalents and $20.764 billion of total long‑term debt and other. Management reaffirmed 2026 guidance, targeting consolidated revenue of $10.67–$10.92 billion and adjusted EBITDA of $3.885–$4.010 billion, and highlighted ongoing Phase 3 development of larsucosterol for alcohol‑associated hepatitis.
Bausch Health Companies Inc. updated how certain 2023 performance share units (PSUs) for two senior executives will be paid out. These PSUs were granted in March 2023, tied to a three-year performance period, and are scheduled to vest on March 3, 2026.
For CEO Thomas Appio, the award agreement covering 1,137,862 2023 PSUs was amended so that, at vesting, the earned PSUs will be settled solely in cash equal to the market price of Bausch Health common shares, using the closing price on the vesting date. For executive Lisa Carson, an agreement provides that she will irrevocably surrender her 137,922 2023 PSUs in exchange for a cash amount based on the same market price definition.
The company notes that full details of the Appio and Carson agreements will be included as exhibits to its Form 10‑Q for the quarter ending March 31, 2026.
Bausch Health Companies Inc. reported solid 2025 growth with some mixed bottom-line items. Fourth-quarter revenue was $2.80 billion, up 9% reported and 6% organically, while full-year revenue reached $10.27 billion, up 7% reported and 5% organically versus 2024.
Full-year GAAP net income attributable to Bausch Health was $157 million, reversing a prior-year loss, but the company posted a fourth-quarter GAAP net loss of $112 million driven by a $145 million goodwill impairment in its Generics unit and a $112 million deferred tax asset valuation allowance. Adjusted net income attributable to Bausch Health was $411 million for the quarter and $1.40 billion for the year, while adjusted EBITDA attributable to Bausch Health rose to $1.05 billion in Q4 and $3.54 billion for 2025.
The company generated $1.40 billion of operating cash flow in 2025, down from $1.60 billion, mainly due to higher working capital and interest payments. Management highlighted 11 consecutive quarters of revenue and adjusted EBITDA growth excluding Bausch + Lomb, the acquisition of Shibo’s aesthetics distribution business in China, and $9.6 billion of 2025 refinancing, including extending $1.6 billion of debt maturities to 2032. For 2026, Bausch Health guides to total revenue of $10.625–$10.875 billion and adjusted EBITDA of $3.875–$4.000 billion, with Bausch Health excluding Bausch + Lomb targeting $1.200–$1.275 billion in adjusted operating cash flow.
Bausch Health Companies Inc. filed a current report to share that it has issued a press release about the results of its global Phase 3 RED-C clinical program. This study evaluated amorphous-rifaximin solid soluble dispersion in adults with liver cirrhosis for the primary prevention of hepatic encephalopathy.
The company furnished the press release as Exhibit 99.1 and stated that this information is being provided under Regulation FD, meaning it is intended as a broad, fair disclosure to the market. The furnished material is not considered "filed" for liability purposes under the Exchange Act or automatically incorporated into other securities filings unless specifically referenced.
Bausch Health Companies Inc. filed a report ahead of its participation in the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The company plans to present at approximately 3:45 p.m. PT (6:45 p.m. ET), where management will share strategic and business updates with investors.
During this presentation, Bausch Health’s management also expects to reaffirm its full-year 2025 guidance at the higher end of the range for Bausch Health excluding Bausch + Lomb Corporation, as previously provided with its third quarter 2025 results. The presentation will be available via live audio webcast, with the materials and a replay posted on the company’s Investor Relations website.
Bausch Health Companies Inc. reports that its subsidiary Bausch + Lomb Corporation has refinanced its term loans by entering into a Fourth Amendment to its Credit and Guaranty Agreement. The amendment establishes a new $2,802,125,000 tranche of term loans maturing on January 15, 2031, with proceeds used to refinance existing term B loans due 2031 and 2028. The new loans amortize at 1.00% per annum, with the first installment due June 30, 2026. The applicable margins are 3.75% per annum for loans tied to term SOFR and 2.75% per annum for loans tied to the alternate base rate, representing reductions of 0.50% and 0.25% per annum compared to the prior tranches. The structure effectively extends the maturity of the earlier 2028 term loans to 2031.
Bausch Health Companies Inc. completed previously announced exchange offers, issuing $1.6 billion aggregate principal amount of new 10.00% Senior Secured Notes due 2032 through its indirect wholly owned subsidiary 1261229 B.C. Ltd. These new notes were exchanged for outstanding 4.875% and 11.00% Senior Secured Notes due 2028 under terms described in a confidential exchange offer memorandum.
The new 2032 notes were issued under an existing indenture structure and form a single series with $4.4 billion principal amount of the Issuer’s existing 10.00% Senior Secured Notes due 2032, sharing the same terms except for interest accrual, consideration and temporary securities identifiers. In connection with this issuance, an additional 26,495,472 common shares of Bausch + Lomb Corporation were pledged, bringing the Issuer’s pledged stake to 211,963,893 shares, representing approximately 60% of Bausch + Lomb’s outstanding common shares as of the settlement date. The existing and new notes are secured by a first priority lien on substantially all assets of the Issuer and other guarantors, including this equity stake.
Bausch Health Companies Inc. reported the final results and expiration of its previously announced debt exchange offers. The company had offered holders of its outstanding 4.875% and 11.00% Senior Secured Notes due 2028 the option to exchange into up to $1.6 billion aggregate principal amount of new 10.00% Senior Secured Notes due 2032, to be issued by its indirect wholly owned subsidiary 1261229 B.C. Ltd. These exchanges were conducted under the terms of a confidential exchange offer memorandum dated November 24, 2025, and expired at 5:00 p.m. New York City time on December 23, 2025. Additional details on the final exchange results are provided in a press release attached as an exhibit.
Bausch Health Companies Inc. reported that its subsidiary Bausch + Lomb Corporation has allocated a new $2,802,125,000 tranche of term B loans, called the Replacement Term Loans, to refinance its existing term B loans due 2031 and 2028. The new loans are expected to carry an applicable margin of 3.75% per annum for loans tied to term SOFR and 2.75% per annum for loans tied to the alternate base rate.
The margins represent a 0.50% per annum reduction versus the existing Third Amendment Term Loans and a 0.25% per annum reduction versus the First Incremental Term Loans. The Replacement Term Loans will mature on January 15, 2031, maintaining the current 2031 maturity while extending the former 2028 maturity. The transactions are anticipated to close in the first quarter of 2026, though completion on these terms is not assured.
Bausch Health Companies Inc. reported the early results of its previously announced debt exchange offers. The company is offering to exchange its outstanding 4.875% Senior Secured Notes due 2028 and 11.00% Senior Secured Notes due 2028 for up to $1.6 billion aggregate principal amount of new 10.00% Senior Secured Notes due 2032, to be issued by indirect wholly owned subsidiary 1261229 B.C. Ltd., under the terms described in a confidential exchange offer memorandum dated November 24, 2025. The update covers early participation results as of 5:00 p.m. New York City time on December 8, 2025, as detailed in an accompanying press release. The company also notes that the new notes will not be registered under U.S. or Canadian public offering rules and may only be offered or sold under applicable exemptions.
Bausch Health Companies Inc. (BHC) has launched exchange offers to swap its outstanding 4.875% and 11.00% Senior Secured Notes due 2028 for up to $1.6 billion aggregate principal amount of new 10.00% Senior Secured Notes due 2032 issued by an indirect subsidiary. The new notes will form a single series with an existing $4.4 billion tranche of 10.00% Senior Secured Notes due 2032 issued earlier in 2025.
Participation is limited to eligible institutional and non‑U.S. holders under U.S. and international securities laws, and acceptances will target a mix of approximately 52.6% 11.00% notes and 47.4% 4.875% notes, subject to a maximum of $1.6 billion. Holders representing about $1,545 million of existing notes, or roughly 46% of the total outstanding, have signed a transaction support agreement committing to tender their notes and to take commercially reasonable actions to facilitate completion of the offers.
Bausch Health Companies Inc. filed a current report to let investors know it has released its financial results for the quarter ended September 30, 2025. On October 29, 2025, the company issued a press release covering its results of operations and other financial information for that quarter, which is included as Exhibit 99.1.
The company states that this information is being furnished, not filed, so it is not subject to certain liability provisions of the Exchange Act and will not be incorporated by reference into securities offering documents. The filing is mainly a formal notice pointing readers to the detailed third-quarter 2025 results contained in the attached press release.
Bausch Health Companies Inc. reported the results of a Special Meeting of Shareholders held on October 7, 2025. Shareholders voted on an ordinary resolution to ratify, confirm and approve the adoption of the company’s Amended and Restated Shareholder Rights Plan Agreement dated April 14, 2025 and amended and restated on August 25, 2025. The resolution was approved, with 178,244,775 votes cast for and 40,130,633 votes cast against. The Rights Plan Agreement is described in detail in the company’s Management Proxy Circular and Proxy Statement dated August 27, 2025.
Bausch Health Companies Inc. disclosed a contractual mechanism tied to the company’s transaction with DURECT Corporation that grants each share a non-transferable contingent value right (CVR). The CVR represents the holder’s pro rata claim on two milestone payments that together can total up to $350,000,000, after deducting retention bonuses payable to certain DURECT employees if the net sales milestones are met. The filing incorporates a September 11, 2025 joint press release and references a Schedule TO Amendment; contact information for the signatory lists Jean-Jacques Charhon as Executive Vice President and Chief Financial Officer.
Bausch Health Companies Inc. reported that its Director Appointment and Nomination Agreement with the Icahn Group, originally signed in February 2021, has terminated after the Icahn Group’s net long position in the company’s shares fell below the required threshold in that agreement. A related supplemental letter agreement dated May 20, 2025 also ended. Both terminations were effective August 14, 2025.
In connection with the end of the appointment and nomination agreement, Brett M. Icahn and Steven D. Miller resigned from Bausch Health’s board of directors on August 14, 2025. Mr. Miller also stepped down from the Board’s Audit and Risk Committee. The company states that their resignations did not result from any disagreement with Bausch Health. On August 15, 2025, the company issued a press release describing these matters.
Bausch Health (NYSE:BHC) disclosed that subsidiary Bausch + Lomb completed a €675 million senior secured floating-rate notes issue due 2031 and entered a Third Amendment to its credit agreement, adding a $2.325 billion term loan maturing 2031 and upsizing its revolver to $800 million maturing 2030.
Proceeds refinanced all term A/B loans and repaid the prior revolver, shifting the nearest debt wall from 2027 to 2031. The notes price at 3-month EURIBOR (0% floor) + 3.875%; the term loans bear SOFR + 4.25% (base-rate option + 3.25%). Covenants include a first-lien net leverage cap of 5.75×, stepping down to 5.50×, plus customary limits on liens, investments and asset sales. Optional redemption is at par after 30 Jun 2026; change-of-control put at 101%.
- Debt issued: €675 m notes & $2.325 b term loan
- Liquidity: new $800 m revolver
- Use of proceeds: refinance 2027 debt & repay revolver